宣泰医药
(688247)
| 流通市值：15.36亿 | | | 总市值：48.92亿 |
| 流通股本：1.42亿 | | | 总股本：4.53亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 108,926,965.45 | 511,619,303.14 | 362,608,213.87 | 217,994,634.76 |
| 营业收入 | 108,926,965.45 | 511,619,303.14 | 362,608,213.87 | 217,994,634.76 |
| 二、营业总成本 | 88,936,260.56 | 384,024,287.06 | 266,457,899.41 | 164,678,881.83 |
| 营业成本 | 65,435,546.45 | 247,466,984.44 | 176,822,016.82 | 111,296,496.43 |
| 税金及附加 | 860,968.84 | 2,713,038.71 | 1,996,359.69 | 1,168,884.9 |
| 销售费用 | 1,876,787.23 | 10,394,841.26 | 6,836,662.01 | 4,525,145.85 |
| 管理费用 | 8,928,620.49 | 44,854,353.91 | 27,716,639.75 | 17,503,026.14 |
| 研发费用 | 12,449,732.66 | 84,924,730.08 | 56,471,663.02 | 34,064,136.64 |
| 财务费用 | -615,395.11 | -6,329,661.34 | -3,385,441.88 | -3,878,808.13 |
| 其中:利息费用 | 164.79 | 2,553.17 | 2,208.77 | 1,666.2 |
| 其中:利息收入 | 706,967.93 | 4,330,643.05 | 3,201,812.22 | 2,280,178.26 |
| 加:投资收益 | 861,541.83 | 12,044,930.79 | 6,995,137.82 | 6,356,440.98 |
| 资产减值损失(新) | -537,368.25 | 1,621,752.05 | 122,816.63 | -1,021,254.23 |
| 信用减值损失(新) | 2,051,750.77 | -3,930,456.51 | -3,420,670.57 | -842,399.91 |
| 其他收益 | 984,713.93 | 6,549,067.8 | 2,920,413.33 | 1,739,729.12 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 23,351,343.17 | 143,880,310.21 | 102,768,011.67 | 59,548,268.89 |
| 加:营业外收入 | 4,027.85 | 5,649.23 | 5,549.16 | 824.78 |
| 减:营业外支出 | 78,379.44 | 1,803,759.21 | 836,057.54 | 292,055.27 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 23,276,991.58 | 142,082,200.23 | 101,937,503.29 | 59,257,038.4 |
| 减:所得税费用 | 2,787,682.49 | 14,381,650.06 | 9,364,528.57 | 5,103,703.52 |
| 六、净利润 | 20,489,309.09 | 127,700,550.17 | 92,572,974.72 | 54,153,334.88 |
| 持续经营净利润 | 20,489,309.09 | 127,700,550.17 | 92,572,974.72 | 54,153,334.88 |
| 归属于母公司股东的净利润 | 20,489,309.09 | 127,700,550.17 | 92,572,974.72 | 54,153,334.88 |
| (一)基本每股收益 | 0.05 | 0.28 | 0.21 | 0.12 |
| (二)稀释每股收益 | 0.05 | 0.28 | 0.21 | 0.12 |
| 八、其他综合收益 | - | 131,292.42 | 10,602.66 | -3,507.81 |
| 归属于母公司股东的其他综合收益 | - | 131,292.42 | 10,602.66 | -3,507.81 |
| 九、综合收益总额 | 20,489,309.09 | 127,831,842.59 | 92,583,577.38 | 54,149,827.07 |
| 归属于母公司股东的综合收益总额 | 20,489,309.09 | 127,831,842.59 | 92,583,577.38 | 54,149,827.07 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-30 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |